Veri’s data platform's goal is to promote progress in precision oncology by collecting up to date predictive biomarkers of drug response. At EMSO-GI 2020, we presented the advances made in the form of cancer-biomarker-drug associations.
The goal of Veri’s data platform is to promote progress in precision oncology by collecting up to date predictive biomarkers of drug response. It collects expert-curated predictive associations (biomarker-cancer-drug) coming from multiple sources like publications, clinical trials or conferences, among others.
Recently, ESMO’s World Congress on Gastrointestinal Cancer (ESMO-GI) took place virtually bringing together the latest achievements in this field. Here, we present the advances made in the form of cancer-biomarker-drug associations, many of which had not been previously reported.
To discover more about ESMO-GI 2020 advances and ultimately the biomarker-drug associations, visit veri.larvol.com. You can access the full plot.ly chart here at: https://chart-studio.plotly.com/~larvol/1/#/
The global pandemic caused by COVID-19 has cast a profound impact on nearly every aspect of our lives. Its effects on health, economics, education, and social structures are apparent, but there are less visible but equally significant impacts too.
Key Opinion Leaders (KOLs) play a crucial role in shaping the success of a drug in the pharmaceutical industry.They are influential figures with expertise, credibility, and a wide network within their respective therapeutic areas. Finding the right KOLs for your drug can significantly impact its development, marketing, and adoption.
If there's one arena where innovation and discovery never cease, it's the pharmaceutical industry. To thrive and stay ahead in this highly competitive field, being in the know of the latest trends and developments is vital.